Last Updated: November 16, 2026

Oliceridine - Generic Drug Details

« Back to Dashboard


What are the generic drug sources for oliceridine and what is the scope of freedom to operate?

Oliceridine is the generic ingredient in one branded drug marketed by Trevena and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

One supplier is listed for this compound.

Summary for oliceridine
International Patents:52
US Patents:5
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 32
Clinical Trials: 22
Patent Applications: 265
What excipients (inactive ingredients) are in oliceridine?oliceridine excipients list
DailyMed Link:oliceridine at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for oliceridine
Generic Entry Date for oliceridine*:
Constraining patent/regulatory exclusivity:
Dosage:

SOLUTION;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for oliceridine

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Xijing HospitalNA
Shiyou WeiNA
Tianjin Medical University General HospitalPHASE4

See all oliceridine clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for oliceridine

US Patents and Regulatory Information for oliceridine

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Trevena OLINVYK oliceridine SOLUTION;INTRAVENOUS 210730-003 Oct 30, 2020 DISCN Yes No 8,835,488 ⤷  Start Trial Y Y ⤷  Start Trial
Trevena OLINVYK oliceridine SOLUTION;INTRAVENOUS 210730-002 Oct 30, 2020 DISCN Yes No 8,835,488 ⤷  Start Trial Y Y ⤷  Start Trial
Trevena OLINVYK oliceridine SOLUTION;INTRAVENOUS 210730-001 Oct 30, 2020 DISCN Yes No 8,835,488 ⤷  Start Trial Y Y ⤷  Start Trial
Trevena OLINVYK oliceridine SOLUTION;INTRAVENOUS 210730-003 Oct 30, 2020 DISCN Yes No 11,931,350 ⤷  Start Trial Y ⤷  Start Trial
Trevena OLINVYK oliceridine SOLUTION;INTRAVENOUS 210730-003 Oct 30, 2020 DISCN Yes No 9,309,234 ⤷  Start Trial Y Y ⤷  Start Trial
Trevena OLINVYK oliceridine SOLUTION;INTRAVENOUS 210730-002 Oct 30, 2020 DISCN Yes No 9,642,842 ⤷  Start Trial Y ⤷  Start Trial
Trevena OLINVYK oliceridine SOLUTION;INTRAVENOUS 210730-001 Oct 30, 2020 DISCN Yes No 9,642,842 ⤷  Start Trial Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Oliceridine Market Dynamics and Financial Trajectory: OLINVYK Sales, Competition, Patents, and Commercial Outlook

Last updated: September 3, 2026

Oliceridine, marketed as OLINVYK by Trevena Inc., has achieved regulatory approval but limited commercial scale. U.S. net product sales rose from launch-level revenue in 2020 to approximately $9 million in 2022 and roughly $10 million to $11 million in 2023. The product competes in a crowded hospital opioid market dominated by inexpensive generic morphine, hydromorphone, fentanyl, and remifentanil. Its commercial proposition depends on hospital adoption of a branded intravenous opioid with a differentiated pharmacology, but the FDA label does not establish a broad clinical exemption from opioid respiratory-depression risk.

What is oliceridine and how is OLINVYK used?

Oliceridine is an intravenous, small-molecule mu-opioid receptor agonist approved for the management of acute pain severe enough to require an opioid analgesic in adults. It is administered in hospitals and other medically supervised settings through clinician-controlled dosing or a patient-controlled analgesia system.

The FDA approved OLINVYK on Aug. 7, 2020, under New Drug Application 210730. The approved indication is limited to short-term use. OLINVYK is not approved for outpatient oral pain management or chronic pain treatment.

Product Active ingredient Sponsor Route FDA approval
OLINVYK Oliceridine Trevena Inc. Intravenous Aug. 7, 2020
Drug class Mu-opioid receptor agonist Trevena Inc. Hospital use Schedule II controlled substance

Oliceridine was designed as a G protein-biased mu-opioid receptor agonist. Trevena positioned the compound as potentially providing analgesia with less respiratory depression and fewer opioid-related adverse effects than conventional opioids. The FDA-approved labeling, however, retains prominent warnings for respiratory depression, abuse, misuse, addiction, overdose, and death. The label does not state that OLINVYK eliminates or materially removes those risks. (U.S. Food and Drug Administration, 2020)

What is the FDA regulatory status of OLINVYK?

OLINVYK has full U.S. approval for acute hospital pain, but its label is narrow and includes important dosing restrictions.

The FDA limits total daily dosing because higher cumulative exposure increases the risk of respiratory depression. OLINVYK is contraindicated in significant respiratory depression, acute or severe bronchial asthma in an unmonitored setting, and known or suspected gastrointestinal obstruction, including paralytic ileus.

The regulatory profile includes:

  • Full FDA approval in 2020.
  • Schedule II classification by the U.S. Drug Enforcement Administration.
  • Hospital-focused intravenous use.
  • No approval for chronic pain.
  • No approved pediatric indication.
  • No approved oral or transdermal formulation.
  • Required monitoring for sedation and respiratory depression.
  • Boxed warnings associated with opioid use.

The product’s regulatory differentiation is therefore narrower than the original pharmacological positioning. Its commercial value depends on whether hospitals perceive an operational or tolerability advantage over low-cost generic opioids.

How much revenue has oliceridine generated?

Trevena’s reported product revenue has remained modest relative to the cost of developing and commercializing an FDA-approved hospital drug.

Fiscal year Approximate OLINVYK net product sales Commercial stage
2020 Less than $1 million U.S. launch year
2021 Approximately $5 million to $6 million Early formulary expansion
2022 Approximately $9 million Broader hospital commercialization
2023 Approximately $10 million to $11 million Slow-growth branded hospital product

Trevena’s filings identify OLINVYK as the company’s principal commercial product. Revenue growth after launch has been positive, but the absolute base remains small. The product has not reached the scale generally required to support a large specialty-pharmaceutical commercial infrastructure without external financing, licensing, or major cost reductions. (Trevena Inc., 2023a; Trevena Inc., 2024)

The financial trajectory has been characterized by:

  1. Initial revenue generation after the 2020 launch.
  2. Incremental hospital adoption rather than rapid formulary conversion.
  3. Continuing operating losses.
  4. Dependence on financing transactions, strategic partnerships, and cost controls.
  5. Limited ability to fund broad clinical expansion from product revenue alone.

Why has OLINVYK adoption been limited?

OLINVYK faces a difficult hospital-market structure. Intravenous opioids are clinically familiar, widely available, and inexpensive. Hospital pharmacy and therapeutics committees often evaluate new opioid products against generic alternatives that have decades of clinical use.

Key adoption barriers include:

  • Generic morphine, hydromorphone, and fentanyl are substantially cheaper.
  • OLINVYK requires hospital formulary review and controlled-substance handling.
  • The product remains subject to the same broad opioid safety concerns.
  • Hospitals may not view the clinical benefit as sufficient to justify a branded premium.
  • Acute-pain protocols are often standardized around established generics.
  • Procurement decisions can be driven by group purchasing organizations and budget controls.
  • The product is limited to supervised intravenous use.
  • The label’s dosing restrictions can reduce perceived flexibility.

OLINVYK’s primary opportunity is not the entire opioid market. It is the subset of hospitalized patients for whom clinicians seek an alternative to conventional IV opioids because of tolerability, dosing, recovery, or workflow considerations.

How does oliceridine compare with competing hospital opioids?

OLINVYK competes with both branded and generic products. The most important competitors are generic injectable opioids rather than other recently launched branded analgesics.

Product Primary hospital role Commercial advantage Commercial weakness versus OLINVYK
Morphine injection General acute pain Very low cost; extensive use Slower onset and familiar opioid tolerability limitations
Hydromorphone injection Severe acute pain High potency; established protocols Respiratory depression and dosing risk
Fentanyl injection Procedural and acute pain Rapid onset; broad availability Short duration and opioid safety risks
Remifentanil Operating-room and procedural analgesia Very short, controllable duration Higher cost and specialized use
OLINVYK Acute hospital pain New pharmacology; branded positioning Higher cost, limited evidence of broad safety superiority

The most relevant commercial question is whether OLINVYK can secure preferred or restricted-preferred formulary status. A non-preferred status would typically limit use to specific patients or require approval by pain specialists, anesthesiologists, or pharmacists.

What clinical evidence supports OLINVYK’s market position?

Trevena’s clinical program included Phase 3 APOLLO studies in postoperative pain and the ATHENA open-label safety study. The development program showed that oliceridine can provide analgesia in acute pain settings. The commercial challenge is that analgesic efficacy alone does not create a strong market advantage when hospitals already have multiple effective generic opioids.

The pharmacological design was intended to separate analgesia from adverse effects associated with beta-arrestin signaling. The FDA review did not treat OLINVYK as free from clinically important opioid respiratory risk. The approved label states that serious and life-threatening respiratory depression can occur.

This distinction matters financially. If the product had received a label-supported, clinically clear respiratory-safety advantage, hospitals could have used it in a differentiated pathway. Without that level of regulatory differentiation, purchasing committees must weigh a potential tolerability benefit against acquisition cost and implementation friction.

When does oliceridine lose exclusivity?

OLINVYK’s market exclusivity depends on several different rights:

  • FDA regulatory exclusivity.
  • Orange Book-listed patents.
  • Patent-term adjustments or extensions.
  • Any later-issued formulation, method-of-use, or manufacturing patents.
  • Generic applicants’ Paragraph IV certifications.
  • Patent litigation and settlement outcomes.

The original approval included five years of new chemical entity exclusivity from the 2020 approval date, subject to statutory exceptions. That period ended in 2025. Patent protection may extend beyond the regulatory exclusivity period, but the practical generic-entry date depends on the validity, enforceability, and scope of the patents listed for the product.

A precise generic-entry forecast requires the current FDA Orange Book patent listing and the status of any abbreviated new drug applications. The publicly reported commercial record does not establish that a generic oliceridine entrant has secured approval or launched.

What patents protect oliceridine and OLINVYK?

Oliceridine’s patent estate has been associated with Trevena’s composition, therapeutic-use, and formulation rights. Public patent records identify issued U.S. patents covering aspects of opioid receptor compounds and their use, but patent scope must be evaluated claim by claim.

Potentially relevant protection categories include:

Composition-of-matter patents

Composition claims generally provide the strongest protection because they can prevent manufacture or sale of the active pharmaceutical ingredient regardless of the approved indication. Their commercial value depends on expiration, terminal disclaimers, patent-term adjustment, and claim validity.

Method-of-use patents

Method patents may cover treatment of acute pain, dosing approaches, or use in defined patient populations. These patents can support litigation against a generic applicant but may be vulnerable to carve-out strategies if the generic label omits the patented indication.

Formulation and delivery patents

OLINVYK is an injectable product. Formulation patents could cover concentration, excipients, stability, vial configuration, or patient-controlled analgesia delivery. Such rights may be narrower than composition patents and may not prevent all generic products if a non-infringing formulation is available.

Manufacturing patents

Manufacturing rights may cover synthetic intermediates, purification, crystallization, or production processes. Process patents can increase the cost and complexity of generic development but generally do not create the same barrier as a valid composition patent.

The strongest practical barrier would be a valid, unexpired composition patent covering oliceridine itself. Formulation and method-of-use patents would provide more limited protection.

Has oliceridine faced Paragraph IV challenges or patent litigation?

No major, publicly established generic launch or definitive Paragraph IV litigation outcome has driven the OLINVYK market through the latest broadly reported commercial period. The absence of a visible generic entrant does not mean that future generic risk is low. The product’s small revenue base may reduce the expected return for a generic manufacturer, which can delay challenge activity until manufacturing economics improve.

Generic-entry risks include:

  • A Paragraph IV challenge to listed patents.
  • A Section viii statement with a label carve-out.
  • Approval after patent expiration without litigation.
  • A competing injectable product that avoids formulation claims.
  • Hospital substitution after a generic obtains FDA approval.
  • Price erosion from authorized or licensed generic supply.

For a product generating around $10 million annually, a generic manufacturer may require a low-cost development and manufacturing pathway to justify entry. That economics-based barrier can be as important as patent protection.

What licensing deals and international opportunities affect oliceridine?

Trevena has pursued commercial and regional partnerships to extend OLINVYK outside direct U.S. commercialization. The company’s strategy has included licensing or partnering discussions for China and other international markets, with the objective of transferring regulatory and commercial costs to regional partners.

International opportunity is constrained by:

  • Opioid-control regulations.
  • Hospital procurement structures.
  • Pricing pressure.
  • Local clinical requirements.
  • Need for controlled-substance distribution infrastructure.
  • Competition from low-cost injectable opioids.
  • Country-specific patent and regulatory expiry dates.

China is potentially attractive because of the scale of its hospital sector, but market access for an injectable opioid requires local regulatory approval, distribution controls, and reimbursement or hospital purchasing access. Regional licensing can produce milestone or royalty revenue, but it does not automatically create material global sales.

How strong is the commercial patent estate for OLINVYK?

The commercial patent estate is strategically useful but does not by itself solve OLINVYK’s market problem.

Patent strength is highest where:

  • A valid composition patent remains unexpired.
  • Claims cover the active ingredient itself.
  • The patent term extends materially beyond regulatory exclusivity.
  • The product has sufficient revenue to support litigation.
  • A generic cannot design around the claims.
  • The FDA listing creates a credible basis for a Paragraph IV dispute.

Patent strength is weaker where:

  • Protection depends mainly on method-of-use claims.
  • The approved indication can be carved out.
  • Formulation claims are narrow.
  • Generic manufacturers can use alternative concentrations or excipients.
  • Annual branded sales remain too low to justify extensive litigation.

OLINVYK’s central commercial risk is therefore not only patent expiry. It is the possibility that the product remains a low-revenue branded hospital opioid even while protected.

What generic launch scenarios exist for oliceridine?

Three generic-entry scenarios are commercially plausible:

Scenario Timing driver Expected effect
Patent-protected delay Valid listed patent survives challenge Trevena retains branded sales until relevant expiry
At-risk launch Generic launches after favorable court ruling or before final resolution Rapid price erosion and hospital substitution
Post-exclusivity entry Generic enters after patents or regulatory barriers expire Material loss of volume and net price

Because injectable hospital products can be substituted through pharmacy procurement, generic entry could produce faster erosion than in a physician-dispensed retail market. OLINVYK’s defense would depend on clinical preference, contracting, supply reliability, and any residual patent protection.

What is the long-term financial outlook for Trevena and OLINVYK?

OLINVYK’s revenue trajectory is more consistent with a niche hospital product than with a mass-market analgesic. Sustained growth would require one or more of the following:

  • Preferred formulary placement.
  • Evidence that reduces concern about respiratory or gastrointestinal adverse effects.
  • Expansion into additional acute-care use cases.
  • International licensing with meaningful commercial milestones.
  • A lower-cost manufacturing and distribution model.
  • Strategic acquisition by a company with hospital sales infrastructure.
  • New indications supported by label expansion.

The downside case is continued low-single-digit or stagnant revenue, followed by accelerated erosion when generic competition becomes commercially attractive. The upside case is a specialized hospital position with recurring use in selected acute-pain pathways, but the product has not demonstrated the sales scale associated with a broad opioid-market displacement strategy.

Key Takeaways

  • OLINVYK is an FDA-approved intravenous oliceridine product for adult acute hospital pain.
  • U.S. sales increased after the 2020 launch but remained approximately $10 million to $11 million in 2023.
  • Trevena has not converted the product into a large commercial franchise.
  • The principal competitors are low-cost generic morphine, hydromorphone, fentanyl, and remifentanil.
  • OLINVYK’s pharmacological differentiation has not produced an FDA label that removes standard opioid respiratory-risk warnings.
  • Five-year new chemical entity exclusivity from the 2020 approval period ended in 2025.
  • Generic risk depends on the current Orange Book listing, patent validity, Paragraph IV activity, and injectable-product economics.
  • Formulation, method-of-use, and manufacturing patents may supplement composition protection but are generally narrower.
  • International licensing may improve capital efficiency but does not eliminate hospital pricing and opioid-control barriers.
  • The product’s financial outlook remains tied to niche formulary adoption, partnerships, and Trevena’s ability to control commercialization costs.

Frequently Asked Questions

Is oliceridine safer than morphine?

Oliceridine was developed to pursue a wider separation between analgesia and certain opioid adverse effects, but the FDA label continues to warn about serious and fatal respiratory depression. It should not be treated as risk-free or broadly safer than morphine based solely on its mechanism.

Is OLINVYK approved for outpatient pain?

No. OLINVYK is approved for acute pain in adults and is administered intravenously in monitored clinical settings. It is not approved as an outpatient oral analgesic.

Who manufactures OLINVYK?

Trevena Inc. owns and commercializes OLINVYK in the United States, using external manufacturing and distribution arrangements associated with commercial pharmaceutical supply.

Can hospitals substitute generic opioids for OLINVYK?

Yes. Hospitals can use generic morphine, hydromorphone, fentanyl, and other opioids as alternatives when clinically appropriate. Formulary placement and procurement contracts largely determine routine use.

What would most improve the value of oliceridine?

The highest-value commercial developments would be durable formulary preference, evidence supporting a clinically meaningful tolerability advantage, successful international licensing, or a strategic transaction with a company that already sells hospital products.

References

  1. Trevena Inc. (2023a). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2022. U.S. Securities and Exchange Commission.

  2. Trevena Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission.

  3. U.S. Food and Drug Administration. (2020). OLINVYK (oliceridine) injection, prescribing information. FDA.

  4. U.S. Food and Drug Administration. (2020). FDA approves new opioid for acute pain in adults. FDA.

  5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

  6. U.S. Drug Enforcement Administration. (2020). Schedules of controlled substances: Oliceridine. Federal Register.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.